Status:
COMPLETED
Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b (" Metronomic Chemotherapy ") for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced Neoplasm
Lead Sponsor:
Institut Paoli-Calmettes
Conditions:
Advanced Neoplasm
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Purpose: This phase I trial estimates the antiangiogenic and antivascular effect of 4 different levels of continuous low doses of the combination of Vinorelbine, Cyclophosphamide and Interferon alpha...
Eligibility Criteria
Inclusion
- patients aged from 18 and older,
- with metastatic or advanced solid tumor who received all standard treatments,
- who ended their chemotherapy or radiotherapy treatment within 4 weeks (6 weeks for mitocyne)prior entry in the study.
- All patients are included after being given written informed consent.
Exclusion
- patients with stable disease,
- history or presence of another cancer,
- contraindication to administer the treatment,
- contraindication to perform MRI,
- pregnancy or breast feeding.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00908869
Start Date
May 1 2006
End Date
May 1 2011
Last Update
January 30 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Paoli-Calmettes
Marseille, France, 13008